布地奈德作为自身免疫性肝炎一线治疗似乎劣于标准泼尼松(龙)给药
这项回顾性多中心研究纳入105例以布地奈德为一线治疗的初治自身免疫性肝炎患者,对照组为276例泼尼松治疗患者。布地奈德组生化应答率显著低于泼尼松组(49% vs 87%,p<0.001),但泼尼松组不良事件风险更高(24.2% vs 15.9%,p=0.047)。
要点
- 布地奈德组生化应答率49%,泼尼松组87%,差异显著(p<0.001)。
- 经逆概率治疗加权倾向评分分析,布地奈德组达成生化应答的概率显著更低(OR=0.20,95%CI 0.11-0.38)。
- 泼尼松组不良事件风险显著更高(24.2% vs 15.9%,p=0.047)。
核心结论
- 在真实临床环境中,布地奈德作为一线治疗使用率低,且通常处方给 perceived 疾病活动度较低的患者。
- 布地奈德作为一线药物劣于泼尼松,但与较少副作用相关。
研究设计与样本
- 回顾性、多中心研究,纳入105例以布地奈德为一线药物治疗的初治自身免疫性肝炎患者,对照组为276例泼尼松治疗患者。
主要发现
- 布地奈德组生化应答中位时间为3.1个月,泼尼松组为4.9个月。
- 泼尼松组生化应答率显著高于布地奈德组(87% vs 49%,p<0.001)。
- 经逆概率治疗加权倾向评分评估,布地奈德组随访期间任何时间达成生化应答的概率显著更低(OR=0.20;95%CI 0.11-0.38)。
- 治疗开始后6个月(OR=0.51;95%CI 0.29-0.89)和12个月(OR=0.41;95%CI 0.23-0.73)布地奈德组达成生化应答的概率均显著更低。
- 在转氨酶低于2倍正常上限的患者中,两组生化应答相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options. APPROACH AND RESULTS: This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, p < 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11-0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29-0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23-0.73). In patients with transaminases <2 × upper limit of normal, BR was similar in both treatment groups. Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs. 15.9%, p = 0.047). CONCLUSIONS: In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.
引用
- Díaz-González Á, Hernández-Guerra M, Pérez-Medrano I, et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology. 2023. PMID: 36626622. doi:10.1097/HEP.0000000000000018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。